We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hematology Analyzer Evaluated for Reliability and Efficiency

By LabMedica International staff writers
Posted on 10 Dec 2012
A high throughput hematology analyzer is found to be reliable, efficient, as well as highly user-friendly and ergonomically designed. More...


A recently introduced series of hematology analyzers are able to carry out complete blood count (CBC), eight-part differential, reticulocyte and erythroblast analysis, as well as body fluids measurements (CBF).

Hematologists at St-Joseph St-Luc Hospital (Lyon, France) evaluated the Pentra DX Nexus analyzers, which offer 50 parameters and a high throughput of 120 samples per hour. The study used the XE-2100 (Sysmex; Kobe, Japan) as a reference system to compare the functions and ergonomics of the workcell. This consisted of a Pentra DX Nexus analyzer, SPS evolution slide maker/stainer and ABX Pentra ML data management system (HORIBA Medical; Northampton, UK).

The results of the evaluations show the instrument’s performance to be very good and the system offers significant improvements over previous generations of the Pentra analyzers for both traceability and ergonomics. The stability and precision functional evaluation of the results demonstrated that the technical abilities of the analyzer fulfilled stringent medical requirements and the manufacturer’s specifications.

A significant improvement in the new Pentra DX Nexus model is the color touch screen that uses easily identifiable icons to denote different functions of the analyzer. The virtual keyboard was found by the study participants to be more useful than a physical keyboard for entering data. Transferring data and hardware connections have also been made easier by multiple USB ports. In addition, a new laser source dissipates less heat and reduces the power requirements and noise generated by the instrument. The study found that the reduced size of the analyzer was also a positive attribute for laboratories, where space is of a premium.

Cleve Wright, General Manager of HORIBA Medical said, “With its new color touch screen and smart access to various functionalities, the Pentra Nexus is an exciting addition to our broad range of Pentra hematology analyzers. All are designed to meet our many differing customer requirements, both in the laboratory and at the point-of-care.”

Related Links:

St-Joseph St-Luc Hospital
Sysmex
HORIBA Medical



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.